Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 589-604

  Maeda, Kenji ^a   Sugino, Haruhiko ^a   Akazawa, Hitomi ^a   Amada, Naoki ^a   Shimada, Jun ^a   Futamura, Takashi ^a   Yamashita, Hiroshi ^a   Ito, Nobuaki ^a   McQuade, Robert D ^b   Mørk, Arne ^c   Pehrson, Alan L ^d   Hentzer, Morten ^c   Nielsen, Vibeke ^c   Bundgaard, Christoffer ^c   Arnt, Jørn ^c   Stensbøl, Tine Bryan ^c   Kikuchi, Tetsuro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

^d LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BREXPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EX VIVO STUDY; FEMALE; HEAD TWITCH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PROTEIN BINDING; QUINOLONES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SEROTONIN; SEROTONIN AGENTS; THIOPHENES;

EID: 84903982078     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213793     Document Type: Article

References (61)

1. Arnt J, Bang-Andersen B, Dias R, and Bøgesø KP (2008) Strategies for pharmacotherapy of schizophrenia. Drugs Future 33:777-791.
2. Arnt J and Hyttel J (1989) Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45-51.
3. Arnt J and Hyttel J (1990) Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques. J Neural Transm 80:33-50.
4. Arnt J and Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
5. 2 receptors. J Pharmacol Exp Ther 302:381-389.
6. Casey DE (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57 (Suppl 11):40-45, discussion 46-52
7. Casey DE, Sands EE, Heisterberg J, and Yang HM (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 200:317-331.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Citrome L (2013) Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 9:193-206.
10. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, and Haddjeri N (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23:177-189.
11. Docherty JR (2010) Subtypes of functional α1-adrenoceptor. Cell Mol Life Sci 67: 405-417.
12. 1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22:2873-2884.
13. du Jardin KG, Jensen JB, Sanchez C, and Pehrson AL (2014) Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 24:160-171.
14. Ebdrup BH, Rasmussen H, Arnt J, and Glenthøj B (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs 20: 1211-1223.
15. Elangbam CS (2010) Drug-induced valvulopathy: an update. Toxicol Pathol 38: 837-848.
16. Fell MJ, Katner JS, Rasmussen K, Nikolayev A, Kuo MS, Nelson DLG, Perry KW, and Svensson KA (2012) Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade. Front Psychiatry 3:49.
17. Fleischhacker WW (2005) Aripiprazole. Expert Opin Pharmacother 6:2091-2101.
18. Flik G, Dremencov E, Cremers TI, Folgering JH, and Westerink BH (2011) The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: an in vivo electrophysiology and microdialysis study. Eur J Neurosci 34:1747-1755.
19. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, and Protter AA (2010) Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 333:748-757.
20. Gross G, Hanft G, and Kolassa N (1987) Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol 336:597-601.
21. Gross G and Drescher K (2012) The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handbook Exp Pharmacol 213:167-210.
22. Hjorth S, Carlsson A, Wikström H, Lindberg P, Sanchez D, Hacksell U, Arvidsson LE, Svensson U, and Nilsson JL (1981) 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28: 1225-1238.
23. Hjorth S, Clark D, and Carlsson A (1988) Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Eur J Pharmacol 152:207-215.
24. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, and Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 208:23-36.
25. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, and Altar CA (2004) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483:45-53.
26. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928.
27. 2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111-3125.
28. Köhler C, Hall H, Ogren SO, and Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
29. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
30. Laoutidis ZG and Luckhaus C (2014) 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol 17:823-832.
31. Leysen JE, Niemegeers CJ, Van Nueten JM, and Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314.
32. Li Z, Ichikawa J, Dai J, and Meltzer HY (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493:75-83.
33. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, and Kikuchi T (2014). Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:605-614.
34. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, and Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411-1417.
35. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2, Suppl)106S-115S.
36. Meltzer HY (2012) Serotonergic mechanisms as targets for existing and novel anti-psychotics. Handbook Exp Pharmacol 212:87-124.
37. 2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc) 46:183-193.
38. Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, and Sanchez C (2013) Vortioxetine (Lu AA21004), a novel multimodal antide-pressant, enhances memory in rats. Pharmacol Biochem Behav 105:41-50.
39. Mørk A, Witten LM, and Arnt J (2009) Effect of sertindole on extracellular dopamine and glutamate in the frontal cortex of conscious rats; a comparison with risperidone and exploration of mechanisms involved. Eur J Pharmacol 206:39-49.
40. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27-35.
41. 1A receptor agonism in antipsy-chotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11:802-812.
42. Newman-Tancredi A, Cussac D, and Depoortere R (2007) Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 8:539-554.
43. 1A receptor properties. Psychopharmacology (Berl) 216:451-473.
44. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 2nd ed, Academic Press, San Diego.
45. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, and Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690.
46. 2C-adre-noceptor modulators: a patent review. Expert Opin Ther Pat 21:455-481.
47. Robinson SW and Caron MG (1997) Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol Pharmacol 52:508-514.
48. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
49. Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimäki J, Piepponen P, Mijatovic J, Tanila H, and Virtanen R, et al. (2013) Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239-249.
50. 2C antagonistic properties of newer antipsychotics. Behav Pharmacol 11:291-298.
51. 2A) receptors. Int J Neuropsychopharmacol 16:1139-1151.
52. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
53. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.
54. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, and Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112.
55. 2A) receptor inverse agonist. J Pharmacol Exp Ther 332:622-631.
56. Stahl SM (2001) Dopamine system stabilizers, aripiprazole, and the next generation of anti-psychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62:923-924.
57. Stip E and Tourjman V (2010) Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther 32 (Suppl 1):S3-S20.
58. 2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10-19.
59. Wong EH, Nikam SS, and Shahid M (2008) Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 9:28-36.
60. Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, and Hiyama T (1988) 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci 42:1941-1954.
61. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsy-chopharmacology 27:248-259.